Therapy Areas: Oncology
US WorldMeds acquires Orbus Therapeutics
28 October 2026 - US-based specialty pharmaceutical company US WorldMeds Ventures LLC announced on Tuesday a definitive merger agreement under which it has acquired Orbus Therapeutics Inc, a privately...
Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044
28 October 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) and Australian biotechnology company Audax Biosciences Pty Ltd announced on Tuesday that they have entered into an excl...
Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult
27 October 2026 - Thor Medical ASA (OSE:TRMED), a supplier of alpha-emitters for precision cancer treatment, said on Tuesday that it has signed a three-year supply agreement with Medicines Discovery C...
Enhertu wins EU approval for HER2-positive early breast cancer treatment
27 October 2026 - Biopharmaceutical company AstraZeneca plc (LSE/STO/NYSE: AZN) and its Japanese pharmaceutical partner Daiichi Sankyo (TYO: 4568) said on Tuesday that the European Commission has appr...
Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418
27 October 2026 - Clinical-stage biotechnology company Riboscience LLC announced on Monday the presentation of initial overall survival (OS) and immune activation data from the Phase 1a/b clinical tri...
Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers
27 October 2026 - Oncology-focused biopharmaceutical company Citius Oncology Inc (Nasdaq:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Monday preliminary...